Keyphrases
Migraine
100%
Erenumab
100%
Calcitonin Gene-related Peptide
100%
Placebo
33%
Headache Intensity
25%
Poor Responders
25%
Antibody Treatment
16%
High Responder
16%
Migraine-like
16%
Area under the Curve
16%
Personal Effectiveness
8%
Migraine Patients
8%
Headache Centres
8%
Peptide Drugs
8%
Randomized Crossover
8%
Between-person
8%
Individual Variance
8%
Standardized Questionnaire
8%
Calcitonin Receptor
8%
Monoclonal Antibody
8%
Placebo-controlled
8%
Intensity Score
8%
Treatment Efficacy
8%
Crossover Design
8%
Denmark
8%
Copenhagen
8%
Medicine and Dentistry
Migraine
100%
Calcitonin Gene Related Peptide
100%
Erenumab
100%
Placebo
45%
Headache
36%
Calcitonin Gene Related Peptide Receptor
9%
Infusion
9%
Biological Marker
9%
Monoclonal Antibody
9%
Combination Therapy
9%
Pharmacology, Toxicology and Pharmaceutical Science
Erenumab
100%
Calcitonin Gene Related Peptide
100%
Migraine
100%
Placebo
45%
Headache
36%
Monoclonal Antibody
9%
Combination Therapy
9%
Calcitonin Gene Related Peptide Receptor
9%
Biological Marker
9%
Neuroscience
Erenumab
100%
Migraine
100%
Calcitonin
100%
Placebo
45%
Headache
36%
Calcitonin Gene-Related Peptide Receptor
9%
Monoclonal Antibody
9%
Biochemistry, Genetics and Molecular Biology
Calcitonin Gene-Related Peptide
100%
Peptide Receptor
8%
Monoclonal Antibody
8%